Case Study: an early-stage company achieves regulatory approval pathway with Kymanox's patient segmentation and PK analysis

A Kymanox Case Study

Strategic Patient Segmentation for Drug Approval Success​

The customer, an early-stage biopharmaceutical company, faced a significant challenge in achieving regulatory approval for its autoinjector combination product. They needed to demonstrate bioequivalence between different patient populations despite device-related pharmacokinetic variability, which was essential for their clinical program to progress. They engaged Kymanox for its expertise in clinical data analysis and regulatory affairs.

Kymanox performed a detailed analysis that identified body mass index (BMI) as a key factor, finding that lower BMI patients experienced greater absorption differences. The solution involved executing a rigorous pharmacokinetic analysis to demonstrate bioequivalence specifically in higher BMI populations. This allowed Kymanox to develop a strategic regulatory positioning that enabled product approval for that select group while establishing a clear contraindication for lower BMI patients. This provided the early-stage company with a viable regulatory pathway forward, enabling continued clinical development and commercialization.


View this case study…

Kymanox

58 Case Studies